Last updated on June 2006

Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma


Brief description of study

The purpose of this multicenter study is to examine whether the proposed randomized treatment regime results in a significantly longer survival time and higher quality of life than any additionally applied multiple chemotherapy according to the CVD- scheme. So far neither established treatment regimes nor reliable data exist for the second-line chemotherapy of metastatic malignant melanoma. Patients are therefore mostly treated with single or multiple chemotherapeutics or/and immunomodulatory therapeutics. These regimes however imply often not only a higher toxicity but show rarely a response rate higher than 10%.

Clinical Study Identifier: NCT00226473

Contact Investigators or Research Sites near you

Start Over

Jens Ulrich, MD

Dept. of Dermatology, University Otto von Guericke
Magdeburg, Germany
8.19miles
  Connect »